Hemogenyx Pharmaceuticals Share Discussion Threads

[badger60] 25/7/2022 09:54

You can avoid DELT because that's the only share that own.

[alancapone] 24/7/2022 15:34

Your total portfolio value nonse?

[badger60] 18/7/2022 09:38

Soon be sub 1p......

[davevtsmummy] 15/7/2022 15:07

Badger, so you have been lied to about your rectum cancer then...you should try dog wormer instead lmao...if we took you to the vets they would put you down.

[longterm3] 14/7/2022 16:32

Tin foil is on offer at Aldi

[replicas1967] 08/7/2022 09:11

hxxps://twitter.com/hemogenyxpharma/status/1545097835925880834?s=21&t=9byAs1LASu44GNgglp8RkA

[badger60] 30/6/2022 11:38

.......to under 1pps.......

[fatgreek] 29/6/2022 11:41

Getting ready to bounce back

[badger60] 29/6/2022 09:51

Lots of happy Hemocasino shareholders waving the Russian flag in honour of Madvlad's riveting performance as CEO......and the share price is still well over 1pps!

[badger60] 24/6/2022 06:38

No... Pressure building as Hemocasino holders are trying to retain chronic diarrhoea...........

[fatgreek] 23/6/2022 12:32

Pressure building getting ready to make a move north.

[fatgreek] 23/6/2022 11:41

Buyers stepping in up she goes could end blue

[jayrh] 22/6/2022 10:17

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration ("FDA") that the proposed pre-Investigational New Drug ("pre-IND") meeting relating to the Company's lead product candidate Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") is to be deferred until May 2022 as a result of a general FDA policy prioritizing work on COVID-19. The deferment of the meeting is not causing any delay in the development of the product candidate. In the meantime, the process will be dealt with by written responses by the FDA to a submission which is now being refined. A pre-IND meeting will then be necessary only if the written responses leave any matters unresolved. In light of this written process now implemented by FDA, there is no anticipated impact from the deferment on the IND filing for HEMO-CAR-T.What's going on?

[jayrh] 22/6/2022 10:00

He said end of may we're now near end of June what's the fda doing

[burtond1] 22/6/2022 07:35

Interesting times ahead for @HemogenyxPharma say @TMSreach "...the most important catalyst for Hemogenyx is Clinical trials..."Co-founder and CEO Dr @vmsandler expands further with @copytaster on the #HEMO pipeline, purity, new facilities and manufacturing associates.https://total-market-solutions.com/2022/06/hemogenyx-pharmaceuticals-plc-june-2022/

[krowelet] 20/6/2022 15:27

yes good confidence and still needs about 2.35p to break even by my calcs. dyor

[idriveajag] 20/6/2022 07:44

If the pre-Ind meeting for Hemo-Car-T was in May, they should get the go ahead for human trials pretty soon. The market for this drug is very large and urgent, so progress will be transformational for the company.Good indication of confidence the Financial Controller bought shares at the end of May.